| Formulary Chapter 5: Infections - Full Chapter
|
| Notes: |
Prescribing of systemic antimicrobials is 'protected'. All prescribing MUST be in accordance with the Trust Antimicrobial Policy and in conjunction with local antimicrobial guideline:
|
|
| Details... |
| 05.03.03.02 |
Chronic hepatitis C |
|
|
Dasabuvir
|
 Restricted
 
|
Provider notes
- NMUH:
- To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth only for Hepatitis C
- Check MHRA Drug Safety Updates
- RFL:
- For use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
 NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
|
Elbasvir + Grazoprevir
|
Restricted
|
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
- RFL:
- Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
|
Glecaprevir + Pibrentasvir
|
Formulary
|
Provider notes - NMUH:
- This medicines has a positive NICE TA and will be included in the formulary once NMUH is able to provide this medicine VAT free.
- RFL:
- Approved for use by Hepatology for the treatment of Hepatitis C in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
|
Ledipasvir + Sofosbuvir
|
Restricted
|
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
- Check MHRA Drug Safety Updates
- RFL:
- Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
|
Ombitasvir + paritaprevir + ritonavir
(Viekirax®)
|
Restricted
|
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by Consultants Andrew Millar, Dimitra Doufexi nd Jonathan Ainsworth ONLY for Hepatitis C.
- Check MHRA Drug Safety Updates
- RFL:
- Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
|
Ribavirin
(Hepatitis)
|
Restricted
|
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for hepatitis B (see NICE TA for eligibility criteria) and chronic hepatitis E viraemia in immunosuppressed individuals (JFC June 2016) Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
- See links below
- Ribavirin is listed on this formulary for treatment of chronic hepatitis C and for immunosuppressed individuals with chronic hepatitis E viraemia
- Ribavirin should only be prescribed by Hepatologists
- RFL:
- Virology/Microbiology/ID approval only.
- Hepatology use approved for the treatment of Hepatitis C in line with NICE guidance and Hepatitis E
- RNOH:
- UCLH:
- WH:
- As per JFC and NICE TA
- Ribavirin should only be prescribed by Hepatologists
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
NICE TA300: Hepatitis C - peginterferon alfa and ribavirin in children and young people
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
|
Sofosbuvir
|
Restricted
|
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
- Check MHRA Drug Safety Updates
- RFL:
- Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C
|
Sofosbuvir + Velpatasvir
|
Restricted
|
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
- Check MHRA Drug Safety Updates
- RFL:
- Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
|
Sofosbuvir + Velpatasvir + Voxilaprevir
|
Restricted
|
Provider notes
- NMUH:
- This medicines has a positive NICE TA and will be included in the formulary once NMUH is able to provide this medicine VAT free.
- RFL:
- Approved for use by Hepatology for the treatment of Hepatitis C in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
|
| .... |
Key |
|
Traffic Light Status Information
| Status |
Description |
|
Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.
Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.
Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity. |
|
Medicines which should normally be prescribed by specialists only (hospital only).
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf |
|
Medicines not recommended for routine use in primary or secondary care.
Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data. |
|
|
|
